Latest news:

Follicum AB receives Notice of Allowance from the U.S. Patent Office for Enhanced Protection of Product Candidate FOL-005

Follicum AB (“Follicum”) announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 15/184,290 which is the company’s second, follow-up application which when granted confers expanded protection for Follicum’s product candidate FOL-005. Follicum has already an approved US patent in this patent family, specifically covering FOL-005. Follicum has […]

Sign up for our Newsletter

Hair growth

Our drug candidate FOL-005 has, in clinical trials, demonstrated increased hair growth on healthy individuals

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




29 Aug 18
LSX Nordic Congress

Follicum will participate, and present, at the LSX Nordic Congress in Stockholm 29-30 August 2018. L...

10 Sep 18
Nordic Life Science Days

Follicum will attend, and present, at the Nordic Life Science Days (NLSD) in Stockholm 10-12 Septemb...